The Red Biotechnology video by Professor Park Tae Hyun from Seoul National University was an informative introduction to the medical aspects of biotechnology that was able to enkindle a newfound interest in the said scientific field within me. Establishing red biotechnology as the field specifically encompassing biopharmaceutics, he begins with a brief explication on the disparity in "complexity," basically the amounts of atoms constituting said molecule, between aspirin, recombinant proteins, and antibodies, where antibodies manifests numbers around 30,000. Then he introduces us to two scientists; Stanley Cohen and Herbert Boyer. The breakthrough they realized in the field of genetic engineering through the development of recombinant DNA, and how its creation was derived from the synergy of the two specialists was elucidated, with the incorporation of a simple diagram delineating the process in which a gene is added to a plasmid vector. After the scientific facets of this development, we are presented the use of the newfound technology by Herbert Boyer to mass-produce certain chemicals by capitalizing upon bacterial organisms' high reproduction rate and its upturn in the insulin market and pharmaceutical industry. He then concludes with the developments in such red biotechnology, and how it changed in recent years. He brings in the concept of biosimilars and generics, and the "Golden Period" for biosimilar technology that transpired during the 2010s, and explicated upon the change in cells used for this task due to the immense complexities of recently mass-produced pharmaceutical drugs. Shedding light on the scientific and commercial intricacies of red biotechnology, or in other words, biopharmaceutics, the video offered me a first glimpse to the scientific particles that act as pillars of such groundbreaking technology, and its use in the market: it provided me an entry point to a relatively recently developed yet highly advanced field.